A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor.
Suzanne GeorgeMichael C HeinrichNeeta SomaiahPeter OppeltRobert McLeodSatoshi NishiokaMadan G KunduXiaozhong QianPrasanna KumarAbderrahmane LaademYvonne LauBrittany P TranMaura FallonOlolade DosunmuJulia ShiYoichi NaitoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Targeting GPR20 with DS-6157a was tolerated in patients with advanced GIST with tumor shrinkage demonstrated in KIT/PDGFRA wild type GIST. However, the study did not proceed further due to lower efficacy outcomes than anticipated.